{
  "id": "9ae714bd-121a-4778-9cab-6e9e4d4b6b9c",
  "patient_id": "bc8a3bb5-01b7-4bbd-a79a-43f812620f3a",
  "encounter_id": "5f9f4650-7af0-451a-813d-6693489bdc44",
  "analysis_type": "Genetic Testing Recommendation",
  "input_text": "Patient: Steven Ortega, DOB: 2006-02-16, Gender: Male\n\nChief Complaint: headache\n\nS: Patient Describes no history of illness\n\nO: No physical exam documented.\n\nA: No assessment documented.\n\nP: No plan documented.\n\n--- IMAGING & SCANS ---\n- ECG (3/25/2025): ECG Scan for Patient\n\n--- IMAGING & SCANS ANALYSIS ---\n\n[Scan 1: ECG (2025-03-25T09:09:28.833517)]\nFile: norm.png\nDescription: ECG Scan for Patient\nAnalysis: Okay, let's analyze this ECG tracing. Here's a detailed breakdown of what I observe, considering it's an ECG scan for a patient:\n\n**Overall Impression:**\n\nThe ECG shows a sinus rhythm, but with some notable findings that warrant further investigation. The rate appears to be around 75 bpm, which is within the normal range. However, there are some concerning changes that suggest potential underlying cardiac issues.\n\n**Detailed Observations:**\n\n1. **Rate:** The heart rate is approximately 75 beats per minute (BPM). This is within the normal range (60-100 BPM). The rhythm appears regular.\n\n2. **R-R Interval:** The intervals between R waves (R-R intervals) are consistent, indicating a regular rhythm.\n\n3. **P Waves:** P waves are present and appear generally normal in morphology. They are upright in leads I, II, aVL, V1, V2, V5, and V6.  However, in lead aVR, the P wave is inverted, which can be seen with certain precordial orientations.\n\n4. **PR Interval:** The PR intervals are within the normal range (0.12-0.20 seconds). \n\n5. **QRS Complex:** This is where the most significant abnormalities are observed.\n   * **QRS Duration:** The QRS complexes appear slightly prolonged, with durations ranging from 0.08 to 0.12 seconds. This prolongation is a key finding.  Normal QRS duration is typically less than 0.10 seconds.\n   * **Morphology:** The QRS complexes are notched and appear somewhat bizarre in leads V1 and V6. This suggests some degree of ventricular depolarization abnormality.  There is a prominent R wave in V1 and V6, which could be indicative of some degree of left ventricular hypertrophy. \n\n6. **ST Segment and T Waves:**\n   * **ST Segment:** The ST segments are generally isoelectric (flat) except for a subtle depression in V4-V6. This could be associated with the QRS prolongation.\n   * **T Waves:** The T waves are predominantly negative, and show some inversion in V1-V3.\n\n7. **Axis:** The QRS axis appears to be predominantly right, as indicated by the upright QRS complexes in leads I, aVF, and V1.  However, the slightly prolonged QRS duration and the morphology\n\n\n--- MEDICAL ENTITY ANALYSIS ---\n\nHISTORY: DOB, 2006-02-16, Male, history of illness\nSIGN_SYMPTOM: Complaint, headache, P waves, P wave, R wave, depression, QRS prolongation, inversion, S\nDIAGNOSTIC_PROCEDURE: physical exam, assessment, IMAGING, S, ECG, ECG tracing, rhythm, rate, heart rate, R-R Interval, between R waves, -R intervals, P Waves, leads I, II, VL, 1, 6, recordial, PR Interval, PR intervals, QRS Complex, QRS Duration, QRS complexes, S duration, ology, leads, ST Segment, T Waves, ST segments, T waves, QRS axis, QR, complexes, leads I, aVF, V1, QRS duration\nLAB_VALUE: P, sinus, 75 bpm, 75 beats per minute, BPM, regular, consistent, normal, upright, inverted, within, 0.12, 0.20 seconds, slightly prolonged, 0., seconds, 0.10 seconds, notched, bizarre, isoelectric, flat, negative, right, prolonged\nDETAILED_DESCRIPTION: 25/2025, -03-25T09:09:28.833517, ,, , a, , V, , V2, V5, and V, lead\nDURATION: 2025\nDISEASE_DISORDER: cardiac issues, ventricular depolarization abnormality, left ventricular hypertrophy\nBIOLOGICAL_STRUCTURE: aVR, V1 and V6, V4-V6, V1-V3\nDISTANCE: 08, 0.12\nSEVERITY: prominent, subtle",
  "recommendation": "recommended",
  "reasoning": "The ECG shows several abnormalities suggestive of a cardiac condition requiring further investigation.  Specifically, the slightly prolonged QRS duration (0.08-0.12 seconds, exceeding the normal range of <0.10 seconds), notched and bizarre QRS complexes in leads V1 and V6, subtle ST depression in V4-V6, and predominantly negative T waves with inversion in V1-V3 are concerning.  These findings, while not definitively diagnostic of any single condition, raise suspicion for several possibilities including, but not limited to,  Long QT Syndrome (LQTS),  Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), or Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).  The literature indicates that LQTS and CPVT can present with normal resting ECGs, making the exercise stress test crucial for diagnosis.  ARVC also often presents with subtle ECG changes in early stages.  The patient's age (19 years old) falls within the typical age range for the onset of symptoms in these conditions.  Given the potential for life-threatening arrhythmias associated with these conditions, genetic testing is strongly recommended to identify a potential underlying genetic cause and guide appropriate management, including preventative measures and potentially life-saving interventions like implantable cardioverter-defibrillators (ICDs).  A detailed family history should also be obtained to assess for familial predisposition to these conditions.",
  "confidence": "70%",
  "model_used": "Gemini-Pro",
  "retrieved_docs": [
    {
      "id": "cvt_txt_3",
      "contents": "\u2022 History of exercise- or emotion-related palpitations and dizziness in some individuals   \n\u2022 Sudden unexpected cardiac death triggered by acute emotional stress or exercise   \n\u2022 Family history of juvenile sudden cardiac death triggered by exercise or acute emotion   \n\u2022 Exercise-induced bidirectional or polymorphic ventricular arrhythmias \u26ac EKG during a graded exercise (exercise stress test) \\* allows ventricular arrhythmias to be reproducibly elicited in the majority of afected individuals. Typically, the onset of ventricular arrhythmias is 90-120 beats per minute. \u26ac With increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the afecte d individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained. \u26ac An alternating $180^{\\circ}$ -QRS axis on a beat-to-beat basis, so-called bidirectional VT, is ofen the distinguishing presentation of CPVT arrhythmias [Priori et al 2021]. \u26ac Notably, some individuals with CPVT may also present with irregular polymorphic VT without a \"stable\" QRS vector alternans [Swan et al 1999, Priori et al 2002]. \u26ac Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fbrillatio n) are common [Leenhardt et al 1995, Fisher et al 1999]. \n\u2022 Ventricular fbrillation occurring in the setting of acute stress \\* Note: Te resting EKG of individuals with CPVT is usually normal. Some authors have reported a lower-thannormal resting heart rate [Postma et al 2005] and others have observed a high incidence of prominent U waves, particularly in the precordial leads [Leenhardt et al 1995, Aizawa et al 2006]. Overall, these features are inconsistent and not sufciently specifc to allow diagnosis. Terefore, in many instances the origin of the syncope may be erroneously attributed to a neurologic disorder. Te exercise stress test is the single most important diagnostic test.",
      "token_count": 485,
      "sentence_count": 15
    },
    {
      "id": "rws_txt_7",
      "contents": "stablishing a specifc genetic cause of long QT syndrome (LQ \u2022 Can aid in discussions of prognosis (which are beyond the scope of this GeneReview) and genetic counseling; \u2022 Usually involves a medical history, physical examination, family history, and genomic/genetic testing. \n\nClinical history. Clinical history in individuals with syncope or a cardiac arrest can reveal specifc triggers for the cardiac event that can be gene specifc. On rare occasions LQTS is accompanied by gene-spe cifc extracardiac features. \nPhysical examination. Te great majority of individuals with LQTS do not have associated physical features. On rare occasions, LQTS is accompanied by gene-specifc extracardiac features. Individuals with EKG characteristics suggestive of a specifc LQTS-associated syndrome (e.g., EKG with T-U patterns characteristic of Andersen-Tawil syndrome) can be assessed for physical features of that syndrome. \nFamily history. A three-generation family history should be taken, with attention to relatives with manifestations of LQTS \u2013 including syncope, aborted cardiac arrest, or sudden death in a child or (young) adult \u2013 and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing and EKG recordings. Specifc focus should also be on triggers of events in relatives, as well as epilepsy (LQTS-associated syncopes may have been attributed to epilepsy). In such instances, review of medical records should include EEG recordings, accompanied by an EKG, which can show QTc prolongation in afected family members. \nEKG evaluation. Te corrected QT (QTc) values on resting EKG and ST-T wave morphology can suggest a specifc genetic cause of LQTS (see Table 2). Additional tests can be helpful to unmask QTc prolongation in individuals with borderline QTc values on resting EKG [Priori et al 2013]: \n\u2022 Exercise EKG, which commonly shows failure of the QTc to shorten normally and even prolongation of the QTc interval [Jervell & Lange-Nielsen 1957, Vincent et al 1991, Swan et al 1998, Horner et al 2011, Sy et al 2011].",
      "token_count": 484,
      "sentence_count": 17
    },
    {
      "id": "barth_txt_9",
      "contents": " Spencer et al [2006] observed that with standard cardiac medications for dilated cardiomyopathy more than 16/30 afected males had normal ejection fraction and lef ventricular diastolic volume. However, some responded to therapy initially but deteriorated afer a period of stability, requiring cardiac transplantation [Adwani et al 1997, Mangat et al 2007]. \nArrhythmia. Te risk for arrhythmia (including supraventricular and ventricular tachycardia) and sudden death is increased. While arrhythmia has been most ofen reported in adolescents and young adults, it can occur in children of all ages. EKG abnormalities can include repolarization abnormalities and prolonged QTc intervals. \nAll 20 afected males with EKGs in the French cohort had a normal sinus rhythm. Repolarization abnormalities (including ST fattening and T-wave inversion) were seen in 17. Five had QTc values within the normal range (QTc ${<}420\\;\\mathrm{ms}_{}$ ), and fve had QTc greater than $460\\:\\mathrm{ms}$ . Te median QTc was $440\\:\\mathrm{ms}$ (range: $360{-}530~\\mathrm{ms})$ ). In the study by Kang et al [2016], nine of 21 afected individuals had prolonged QTc of greater than $460~\\mathrm{ms}$ and three had borderline QTc prolongation between 450 and $460~\\mathrm{ms}$ . \nIn fve instances of ventricular arrhythmia leading to cardiac arrest or placement of an internal defbrillato r [Spencer et al 2005]: \n\u2022 All fve individuals had normal QTc intervals;   \n\u2022 All fve had a history of recurrent vasovagal symptoms including postural dizziness, nausea, and pallor suggestive of autonomic instability;   \n\u2022 Four had only mild LV dilatation and low normal to mildly depressed LV function; only one had poor but stable LV function prior to cardiac arrest;   \n\u2022 Tree showed inducible ventricular arrhythmias on electrophysiologic testing;   \n",
      "token_count": 479,
      "sentence_count": 15
    },
    {
      "id": "rws_txt_1",
      "contents": " Tis idea is incorporated in the LQTS diagnostic scoring system proposed in the European Society of Cardiology guidelines for management of LQTS [Zeppenfeld et al 2022] (see Table 1). A LQTS risk score of $>\\!3.0$ in the absence of a secondary cause for QT prolongation is sufcient for a diagnosis of LQTS. \nCardiac Features \nT wave abnormalities include T wave alternans, notched T wave, broad-based and fattened T waves (see Adler et al [2020] and Wilde et al [2022] for concise examples and Tardo et al [2023] for a comprehensive review) and are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is \nusually self-terminating and may cause palpitations, dizziness, or syncope, the most common symptom in individuals with LQTS. Syncope is typically precipitous and without warning. A careful evaluation of medical history can help distinguish LQTS-associated syncope from common vasovagal and orthostatic forms of syncope in which presyncope and other warning symptoms occur. Absence of aura, incontinence, and postictal fndings help diferentiate LQTS-associated syncope from seizures. Te number of syncopal events in symptomatic individuals ranges from one to hundreds, averaging just a few. In some instances, TdP degenerates to ventricular fbrillation and aborted cardiac arrest (if the individual is defbrillated) or sudden death. \nCardiac events (i.e., syncope, cardiac arrest, or sudden cardiac death) may occur from infancy through middle age but are most common from the preteen years through the 20s, with the risk generally diminishing throughout that time period. Te usual age range of events difers somewhat for each genotype. Cardiac events are uncommon afer age 40 years; when present, they are ofen triggered by administration of a QT-prolonging drug or hypokalemia. Cardiac events in individuals over age 40 years are more likely associated with SCN5Arelated LQTS. \n",
      "token_count": 479,
      "sentence_count": 16
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_767",
      "contents": "LQT syndrome is caused by repolarization defects in cardiac cells. Repolarization is a controlled process that requires a balance between inward currents of sodium and calcium and outward currents of potassium. Imbalances cause the action potential of cells to increase or decrease in duration, causing elongation or shortening, respectively, of the QT interval on electrocardiography. Most cases of LQT syndrome are caused by loss-of-function mutations in genes that encode subunits or regulatory proteins for potassium channels (genes whose names begin with KCN). These mutations decrease the outward, repolarization current, thereby prolonging the action potential of the cell and lowering the threshold for another depolarization. In other LQT syndrome patients, gain-of-function mutations in a sodium channel gene, SCN5A, lead to an increased influx of sodium, resulting in similar shifting of action potential and repolarization effects. \nPhenotype and Natural History \nThe LQT syndromes are characterized by elongated QT interval and T-wave abnormalities on electrocardiography (Fig. C-28), including tachyarrhythmia and torsades de pointes, a ventricular tachycardia characterized by a change in amplitude and twisting of the QRS complex. Torsades de pointes is associated with a prolonged QT interval and typically stops spontaneously but may persist and worsen to ventricular fibrillation. \n\nIn the most common LQT syndrome, Romano-Ward, syncope due to cardiac arrhythmia is the most frequent symptom; if undiagnosed or left untreated, it recurs and can be fatal in $10\\%$ to $\\bar{1}5\\%$ of cases. However, between $30\\%$ and $50\\%$ of individuals with the syndrome never show syncopal symptoms. Cardiac episodes are most frequent from the preteen years through the 20s, with the risk decreasing over time. Episodes may occur at any age when triggered by QTprolonging medications (see list at http://www.qtdrugs.org). Nonpharmacological triggers for cardiac events in the Romano-Ward syndrome differ on the basis of the gene responsible. LQT1 triggers are typically adrenergic stimuli, including exercise and sudden emotion.",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "arvd_txt_19",
      "contents": " A study in younger individuals suggested that cardiac MRI was more sensitive than echocardiogram but that it was still unusual, even with cardiac MRI, to identify ARVC in children before age ten years [Etoom et al 2015]. \nIn children younger than age 18 years. Te 2010 Task Force Criteria [Marcus et al 2010] should be used with caution, as many of the EKG diagnostic criteria are a normal fnding in children, such as inverted T waves in right precordial leads (V1, V2, and V3) [Te Riele et al 2021]. Cardiac MRI has been shown to have a better positive predictive value (and especially data from echocardiogram and cardiac MRI combined) [Steinmetz et al 2018, Te Riele et al 2021]. \nRecommendations for Medical and Surgical Management of ARVC \nAfected individuals should be monitored by a cardiologist who is knowledgeable about ARVC. Management of individuals with ARVC is complicated by its variable course and the limited specifcity of clinical fndings to predict arrhythmia risk. Management should be individualized and based on the specifc results of detailed clinical and genetic investigation. \nGene-Specific Management Recommendations \nDSP. Because of the risk of lef ventricular dysfunction associated with $D S P$ pathogenic variants [Smith et al 2020], management for individuals with $D S P$ -related ARVC should address monitoring and management for  lef ventricular dysfunction, including guideline-directed therapy [Towbin et al 2019, Heidenreich et al 2022]. \nGeneral Management Recommendations for ARVC \nTreatment recommendations for ARVC can be found in an international task force consensus statement [Corrado et al 2015]. Additional guidance is found in the American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of individuals with ventricular arrhythmias and the prevention of sudden cardiac death [Al-Khatib et al 2018] and in an updated Heart Rhythm Society guideline for arrhythmogenic cardiomyopathy [Towbin et al 2019]. \n\u2022 Management is focused on prevention of syncope, cardiac arrest, and sudden death (see Prevention of Primary Manifestations).   \n",
      "token_count": 470,
      "sentence_count": 14
    },
    {
      "id": "arvd_txt_9",
      "contents": "Molecular genetic testing is recommended in individuals who both fulfll diagnostic criteria as well as those with suspected arrhythmogenic right ventricular cardiomyopathy (ARVC) to (1) confrm the diagnosis of ARVC, as identifcation of an ARVC-related pathogenic variant is a major diagnostic criteria in the 2010 Task Force Criteria [Marcus et al 2010]; (2) guide management in those with more than one ARVC-related pathogenic variant identifed [Towbin et al 2019, James et al 2021]; and (3) enable testing of at-risk relatives (see Genetic Risk Assessment and Surveillance for Cardiac Involvement). \nNote: American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of ventricular arrhythmias and prevention of sudden cardiac death recommend genetic counseling and molecular genetic testing for individuals with clinically diagnosed or suspected ARVC as a class IIa recommendation (i.e., a moderate level of evidence supports the recommendation is reasonable, can be useful/efective/benefcial, and the benefts outweigh the risks) [Al-Khatib et al 2018]. \nEstablishing the specifc genetic cause of ARVC usually involves an evaluation with a cardiologist including medical history, physical examination, cardiology assessment, family history, and molecular genetic testing. Note: Molecular genetic testing should begin with a proband with a clinical diagnosis of ARVC or suspected ARVC rather than an unafected family member; molecular testing of an afected individual will provide the most informative results [James et al 2021]. \nMedical Evaluation \nMedical history and physical examination are directed at identifying physical features associated with spe cifc genetic causes of ARVC (Table 1). \nCardiology evaluation includes imaging to visualize the right ventricle, stress testing, and telemetric cardiac rhythm monitoring, as dictated by personal and family history. \nFamily history should include a three-generation family history with attention to heart palpitations, syncope, and sudden death in relatives; and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing, cardiovascular and physical examinations, and postmortem examination.",
      "token_count": 472,
      "sentence_count": 9
    },
    {
      "id": "cantu_txt_19",
      "contents": " J wave syndromes. Heart Rhythm.",
      "token_count": 8,
      "sentence_count": 2
    },
    {
      "id": "salih-myo_txt_1",
      "contents": "Agents/circumstances to avoid: Ibuprofen in those with congestive heart failure. \nGenetic counseling \nSalih myopathy is inherited in an autosomal recessive manner. Te parents of an afected child are obligate heterozygotes (i.e., carriers of one pathogenic variant) and are asymptomatic. At conception, each sib of an afected individual has a $25\\%$ chance of being afected, a $50\\%$ chance of being an asymptomatic carrier, and a $25\\%$ chance of being unafected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family have been identifed. \nDiagnosis \nSuggestive Findings \nSalih myopathy should be suspected in individuals with the following clinical, laboratory, electrophysiologic, imaging, and histopathology fndings. \nClinical \n\u2022 Muscle weakness manifesting during the neonatal period or in early infancy   \n\u2022 Delayed motor milestones but normal cognitive development   \n\u2022 Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy   \n\u2022 Development of dilated cardiomyopathy between ages fve and 16 years   \n\u2022 Major heart rhythm disturbances leading to sudden death before age 20 years \nm creatine kinase (CK) is marginally to moderately increase \nElectrophysiologic \n\u2022 Electrocardiography. Lef axis deviation (lef anterior fascicular block) can be seen as early as age four years (Figure 1). With the onset of dilated cardiomyopathy, rhythm disturbances can include polymorphic premature ventricular complexes, bigeminism and trigeminism, couplets, triplets, atrioventricular heart block, atrioventricular nodal reentrant tachycardia, premature atrial complexes, premature ventricular complexes, and ventricular tachycardia.   \n\u2022 Electromyography shows myopathic features (low-amplitude polyphasic potentials of short duration).   \n\u2022 Nerve conduction studies are normal. \n",
      "token_count": 452,
      "sentence_count": 21
    },
    {
      "id": "rws_txt_41",
      "contents": "Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187\u201394. PubMed PMID: 22042885.   \nTardo DT, Peck M, Subbiah RN, Vandenberg JI, Hill AP. Te diagnostic role of T wave morphology biomarkers in congenital and acquired long QT syndrome: a systematic review. Ann Noninvasive Electrocardiol. 2023;28:e13015. PubMed PMID: 36345173.   \nTester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507\u201317.",
      "token_count": 241,
      "sentence_count": 14
    },
    {
      "id": "dcm-lmna_txt_0",
      "contents": "LMNA-Related Dilated Cardiomyopathy \nRay E Hershberger, ${\\mathsf{M D}}^{1}$ and Elizabeth Jordan, MMSc, CGC2 Created: June 12, 2008; Updated: March 17, 2022. \nSummary \nClinical characteristics \nLMNA-related dilated cardiomyopathy (DCM) is characterized by lef ventricular enlargement and/or reduced systolic function preceded (sometimes by many years) by or accompanied by conduction system disease and/or arrhythmias. LMNA-related DCM usually presents in early to mid-adulthood with symptomatic conduction system disease or arrhythmias, or with symptomatic DCM including heart failure or embolus from a  lef ventricular mural thrombus. Sudden cardiac death can occur, and in some instances is the presenting manifestation; sudden cardiac death may occur with minimal or no systolic dysfunction. \nDiagnosis/testing \nTe diagnosis of LMNA-related DCM is established in a proband with suggestive fndings and a heterozygous pathogenic variant in LMNA identifed by molecular genetic testing. \nManagement \nTreatment of manifestations: Chronic atrial fbrillation is treated initially with attempts to restore normal sinus rhythm, anticoagulation, and rate control. Symptomatic supraventricular arrhythmias are usually treated with pharmacologic therapy or ablation; symptomatic bradyarrhythmias or signifcant heart block is treated with an electronic pacemaker. Symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fbrillation, and resuscitated sudden cardiac death are treated with an implantable cardioverter defbrillator (ICD) and drug therapy as needed. Because risk for sudden cardiac death in LMNA-related DCM accompanies heart block and bradyarrhythmias, ICD use (rather than just pacemaker use) has been recommended for all indications. Treatment of symptomatic DCM, including heart failure, is pharmacologic with ACE inhibitors, beta blockers, and other conventional approaches. Progressive deterioration in lef ventricular function is treated with an ICD.",
      "token_count": 491,
      "sentence_count": 14
    },
    {
      "id": "arvd_txt_6",
      "contents": "\u2022 Minor \u26ac Late potential by signal-averaged EKG in at least one of three parameters in the absence of a QRS duration of ${\\geq}110~\\mathrm{ms}$ on standard EKG \u26ac Filtered QRS duration $(\\mathrm{fQRS})\\,{\\geq}114\\,\\mathrm{ms}$ $^\\circ$ Duration of terminal QRS ${<}40\\,\\mathrm{uV}$ (low-amplitude signal duration) ${\\geq}38$ ms \u26ac Root-mean-square voltage of terminal $40\\;\\mathrm{ms}\\leq20\\;\\mathrm{uV}$ \n\u26ac Terminal activation duration of $\\mathrm{QRS}>55~\\mathrm{ms}$ measured from the nadir of the S wave to the end of the QRS, including $\\mathrm{R}^{\\prime}$ , in V1, V2, or V3 in the absence of complete right bundle branch block \nArrhythmias \n\u2022 Major. Nonsustained or sustained ventricular tachycardia of lef bundle branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)   \n\u2022 Minor \u26ac Nonsustained or sustained ventricular tachycardia of RV outfow confguration, lef bundle branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis \u26ac ${>}500$ ventricular extrasystoles per 24 hours (Holter) \nFamily History and Molecular Genetic Testing \nMajor \n\u2022 ARVC confrmed in a frst-degree relative who meets 2010 Task Force Criteria [Marcus et al 2010] \u2022 ARVC confrmed pathologically at autopsy or surgery in a frst-degree relative \u2022 Identifcation of a pathogenic variant categorized as associated or probably associated with ARVC in the proband \nMinor \n",
      "token_count": 433,
      "sentence_count": 6
    },
    {
      "id": "jln_txt_15",
      "contents": "Therapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nOther \nFamily members of individuals with JLNS should be trained in cardiopulmonary resuscitation (CPR) as up to $95\\%$ of individuals with JLNS have a cardiac event before adulthood [Schwartz et al 2006]. \nAfected individuals should wear an ID bracelet explaining their diagnosis. \nIt is appropriate to notify local emergency medical services (EMS) of high-risk persons, including those with JLNS [Hazinski et al 2004]. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nJervell and Lange-Nielsen syndrome (JLNS) is inherited in an autosomal recessive manner. \nRisk to Family Members \nParents of a proband \n\u2022 Parents of a child with JLNS are usually obligate heterozygotes (i.e., carriers of one KCNQ1 or KCNE1 pathogenic variant). In rare cases, only one parent is heterozygous and the other pathogenic variant in the proband is de novo [Schwartz et al 2000].   \n\u2022 Parents may or may not have the long QT syndrome (LQTS) phenotype. Studies have documented autosomal dominant inheritance of moderately prolonged QTc intervals in some, but not all, families in which one or more sibs have JLNS [Splawski et al 1997].   \n\u2022 Recommendations for evaluation of the parents of a child with JLNS include: \u26ac Molecular genetic testing if the pathogenic variants have been identifed; \u26ac Comprehensive electrocardiographic testing for evidence of QTc prolongation by a physician familiar with LQTS. \nSibs of a proband \n",
      "token_count": 482,
      "sentence_count": 21
    },
    {
      "id": "acpp_txt_15",
      "contents": " \u2022 If the pathogenic variant in the family is not known, detailed neurologic and cardiologic evaluation, 12- lead EKG, and 24-hour Holter monitoring can be used to clarify the disease status of at-risk relatives. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nTe rarity of ATS and the paucity of reports pertaining to pregnancy in women with ATS make an evidencebased approach to pregnancy management difcult to formulate. One case study reported an uneventful pregnancy, with increased episodes of weakness but reduced ventricular ectopy compared to the pre-pregnancy period [Subbiah et al 2008]. However, as data are limited, a multidisciplinary approach to individual care and anticipation of increased risk (as can be seen in those with long QT syndrome) seems reasonable. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nAndersen-Tawil syndrome (ATS) is inherited in an autosomal dominant manner. \nRisk to Family Members \nParents of a proband \n\u2022 At least $50\\%$ of individuals diagnosed with ATS have an afected parent. \u2022 A proband with ATS may have the disorder as the result of a de novo KCNJ2 pathogenic variant.  Te proportion of cases caused by a de novo pathogenic variant in KCNJ2 may be as high as $50\\%$ .",
      "token_count": 433,
      "sentence_count": 20
    },
    {
      "id": "26431_txt_22",
      "contents": " For the connective tissue disorders identifed in task 1, identify the types of treatments available and describe to the degree possible: \na. The clinical practice guidelines for receiving the treatments;   \nb. The settings in which the treatments are provided;   \nc. What receipt of the treatments indicates about the clinical or medical severity of the medical condition;   \nd. The likelihood of improvement when receiving the treatments and the period over which the improvement would be expected; and   \ne. Any limitations on the availability of the treatments (other than due to fnancial circumstances or the patient\u2019s preferences), such as whether treatments are considered experimental, remain in the trial phase, or are limited to certain geographic areas. \n\n4. For the connective tissue disorders identifed in task 1, provide a summary of selected treatments currently being studied in clinical trials. \n5. For the connective tissue disorders identifed in task 1, identify to the degree possible the functional limitations associated with each disorder, including physical functioning limitations, mental functioning limitations, limitations resulting from common treatments, and variations in functioning (e.g., during fare-ups vs. remission), and how such limitations would present in a typical medical record. \n6. For the connective tissue disorders identifed in task 1, identify nonexertional physical limitations (e.g., balancing or using the upper extremities for fne or gross movements) and mental limitations (e.g., cognitive or behavioral) that are equivalent in severity to the standard represented in the listings (i.e., that would prevent any gainful activity) but are not captured by currently existing listings and are not currently refected in SSA\u2019s disability grid rules. \nrt will include consensus conclusions but not recommenda \nIn the report, when terms such as \u201cseverity\u201d or \u201csevere\u201d are used, the committee shall identify to the degree possible whether the term is being used with SSA\u2019s work-related program defnition (i.e., an impairment of such severity as to be the basis of a fnding of an inability to engage in any substantial gainful activity) or as it is used in the clinical or medical care settings, and, if necessary, will specify the pertinent differences between the two defnitions. \nThe committee shall not describe issues with respect to access to treatments due to fnancial circumstances, including insurance limitations.",
      "token_count": 492,
      "sentence_count": 18
    },
    {
      "id": "del2q37_2_txt_10",
      "contents": "\u2022 Complete physical and dysmorphology examination   \n\u2022 Determination of head circumference, height, weight, and other anthropometric measurements   \n\u2022 Specialty evaluation of obesity or failure to thrive   \n\u2022 Multidisciplinary developmental and neurologic evaluation to assess motor and cognitive skills as well as autism, autism spectrum behaviors, and other behavioral issues   \n\u2022 Echocardiogram to evaluate for congenital cardiac anomaly   \n\u2022 Renal ultrasound examination to evaluate for possible Wilms tumor, renal malformation, or other renal problems Ophthalmology evaluation for strabismus and/or refractive errors   \n\u2022 Audiologic assessment for possible hearing loss   \n\u2022 Brain imaging studies (MRI, CT scan) in individuals with abnormal neurologic fndings   \n\u2022 EEG for evaluation of seizures and treatment monitoring   \n\u2022 X-ray to evaluate for the presence of scoliosis and skeletal anomalies examination. While the clinical implications of osteopenia have not been studied in the 2q37 microdeletion syndrome, clinicians should be aware that this is a common fnding. X-rays should be performed at diagnosis and should be repeated as warranted by clinical examination. Te youngest individual with osteopenia in the authors' series is age three years.   \n\u2022 Consultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nDepending on the age and presenting concerns of the individual with the 2q37 microdeletion syndrome, care from specialists in the following areas is ofen necessary: clinical genetics, speech pathology, occupational and physical therapy, child development, neurology, cardiology, gastroenterology, nutrition/feeding in cases of failure to thrive, ophthalmology, and audiology. \nMedical care may be coordinated by a clinical geneticist or other health care professional skilled at managing patients with complex needs. \nInfants beneft from enrollment in an early-intervention program. Most school-age children beneft from an individualized educational program (IEP) with input from a multispecialty group of physical, occupational, and speech therapists with pediatric assessment. \nPrevention of Secondary Complications \nAt this time, it is not known why many individuals with the 2q37 microdeletion syndrome are obese. To the extent that it is feasible, the authors recommend an active lifestyle and good dietary habits to help avoid development of obesity. \nSurveillance \n",
      "token_count": 475,
      "sentence_count": 23
    },
    {
      "id": "kmt2b-dystonia_txt_11",
      "contents": "Early initiation of physiotherapy and a tailored exercise program is essential to maintain function and prevent secondary orthopedic complications such as joint contractures, hip dislocation, and/or kyphoscoliosis. \nAdaptive aids (e.g., ankle-foot orthoses, walkers) should be supplied to support and maintain ambulation. \nSpeech and language therapy is crucial to assist in feeding skills and communication. Some afected individuals may need communication devices. \nNutrition specialists / dieticians are of utmost importance to assess calorie needs and reduce the risk of malnutrition. \nVideofuoroscopy can be used to evaluate the risk of aspiration and assess the need for alternative means of feeding. \nFor individuals with respiratory compromise from chest deformities related to scoliosis, prophylactic antibiotics during the winter months, regular physiotherapy, and infuenza immunizations should be considered because of the increased risk of pulmonary infections. \nDevelopmental Delay / Intellectual Disability Management Issues \nTe following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. \nAges 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states. \nAges 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed. \nAges 5-21 years \n\u2022 In the US, an IEP based on the individual's level of function should be developed by the local public school district. Afected children are permitted to remain in the public school district until age 21. \u2022 Discussion about transition plans including fnancial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood. \nAll ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. \nConsideration of private supportive therapies based on the afected individual's needs is recommended.",
      "token_count": 474,
      "sentence_count": 23
    },
    {
      "id": "christianson_txt_9",
      "contents": "\u2022 Establishment of baseline neurologic functioning with: \u26ac Assessment of adaptive functioning (e.g., Vineland, Bayley Scales of Infant Development) \u26ac Occupational therapy and physical therapy assessment regarding fne motor and gross motor functioning \u26ac Speech/language/communication assessment \u26ac Assessment of behavioral issues, as needed, using such evaluation tools as Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview-Revised (ADI-R)] \u26ac Neurologic examination \u26ac EEG \u26ac Brain MRI (based on the clinician's judgment) to determine if any structural brain abnormalities are present, especially cerebellar / brain stem atrophy   \n\u2022 Evaluation of swallowing function, feeding, and nutrition as needed   \n\u2022 Ophthalmologic assessment, including evaluation for eye movement abnormalities and visual acuity, when warranted   \n\u2022 Consultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nDevelopmental Delay / Intellectual Disability Management Issues \nTe following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. \nAges 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states. \nAges 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies, and an individualized education plan (IEP) is developed. \nAges 5-21 years \n\u2022 In the United States, an IEP based on the individual's level of function should be developed by the local public school district. Afected children are permitted to remain in the public school district until age 21. Discussion regarding transition plans and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood. \nAll ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. \nConsideration of private supportive therapies based on the afected individual's needs is recommended. Spe cifc recommendations regarding type of therapy can be made by a developmental pediatrician. \nIn the US: \n\u2022 Developmental Disabilities Administration (DDA) enrollment is recommended.",
      "token_count": 473,
      "sentence_count": 23
    },
    {
      "id": "saul-wilson_txt_8",
      "contents": "BCVA $=$ best-corrected Snellen visual acuity; $\\mathrm{BMD}=$ bone mineral density; $\\mathrm{ERG=}$ electroretinography; FTT $=$ failure to thrive; $\\mathrm{HC}=$ head circumference; $H\\Gamma=$ height; $\\mathrm{OCT=}$ optical coherence tomography; $\\mathrm{OT}=$ occupational therapy; $\\mathrm{PT}=$ physical therapy; ${\\mathrm{SNHL}}=$ sensorineural hearing loss; $\\mathrm{SWS}=:$ Saul-Wilson syndrome; ${\\mathrm{WT}}=$ weight   \n1. See Hereditary Hearing Loss and Deafness Overview for details about audiologic evaluations. \nTreatment of Manifestations \nable 4. Treatment of Manifestations in Individuals with Saul-Wilson Syn \nDevelopmental Delay Management Issues \nTe following information represents typical management recommendations for individuals with developmental delay in the United States; standard recommendations may vary from country to country. \nAges 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs. \nAges 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. Te early intervention program typically assists with this transition. Developmental preschool is center based. \nAll ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider: \nIEP services: \n\u26ac An IEP provides specially designed instruction and related services to children who qualify. \u26ac IEP services will be reviewed annually to determine whether any changes are needed. \u26ac Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.",
      "token_count": 481,
      "sentence_count": 20
    },
    {
      "id": "A_Guide_To_Marfan_Syndrome_and_Related_Disorders_txt_14",
      "contents": " More information about these disorders is provided in section V of this book. \nNo specific diagnosis \nThis is when a person has Marfan features but does not meet the diagnostic criteria for any known disorder. Many people with \nMarfan features (whether they have a diagnosis or not) need medical treatment and follow-up care. Make sure to talk with your doctor about the care that is right for you. \nMany people with Marfan features (whether they have a diagnosis or not) need medical treatment and follow-up care. Talk with your doctor about the care that is right for you. \n1.ROUTINE TREATMENT \nThere is no cure for Marfan syndrome. However, a range of treatment options can minimize and sometimes prevent complications. Appropriate specialists will develop individualized treatment programs and the approach a doctor uses depends on which systems are affected. \nEvery person needs a physician who can be turned to for \u201croutine\u201d illnesses and questions. Most physicians who provide these services know about Marfan syndrome only superficially, and may not feel comfortable taking care of the specialized problems that people with Marfan syndrome might develop. In addition to a personal physician (usually an internist, pediatrician or general practitioner), it is important to have one doctor who understands all aspects of Marfan syndrome\u2014someone who can evaluate all of the systems that might be affected, coordinate referral to specialists when needed, and counsel about prognosis, treatment and inheritance. \nThis doctor may be a medical geneticist, most of whom tend to be located at medical centers affiliated with medical schools, as are many of the specialists who have the most experience with Marfan syndrome. For most people, an annual or semi-annual visit to such a center will provide the necessary medical follow-up for Marfan syndrome. \nFollowing are some of the important treatment considerations by body system. \nAbout half of all people with Marfan syndrome develop scoliosis, although only about one third of those need treatment. \nA. Bones & Joints (Skeletal System) \ni. Scoliosis \nScoliosis is a spinal curvature in which the vertebrae twist, usually into an S-shape or spiral shape. It is caused by the abnormally loose ligaments of the spine and the rapid growth of the child with Marfan syndrome. Scoliosis can affect any part of the spine, and it may be mild or severe.",
      "token_count": 468,
      "sentence_count": 23
    },
    {
      "id": "sca37_txt_8",
      "contents": "Evaluations Following Initial Diagnosis \nTo establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 37 (SCA37), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended: \nPhysical examination \n\u2022 Neurologic assessment   \n\u2022 Assessment of the full range of symptoms associated with a progressive cerebellar syndrome. Among a range of clinical scoring systems that have been described [Saute et al 2012], the Scale for the Assessment and Rating of Ataxia (SARA) [Schmitz-H\u00fcbsch et al 2006] provides a reliable and consistent assessment of most of the clinical features and progression of SCA37.   \n\u2022 Electrooculographic tests may properly assess progression at the onset of disease.   \n\u2022 Specifc assessment of the cerebellar cognitive afective syndrome may be considered.   \n\u2022 Brain MRI examination   \n\u2022 Consultation with speech, physical, behavioral, and occupational therapists   \n\u2022 Consultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nNo curative treatment is available for individuals with SCA37. Palliative care includes the following: \nSpeech therapy to improve communication and ameliorate dysphagia Tickness modifcation of food and fuids to prevent aspiration Physical therapy to train balance \u2022 Use of external devices (e.g., canes or walkers) when needed to avoid falls \u2022 Occupational/behavior therapy \nSurveillance \nTe following are appropriate: \n\u2022 SARA score annually. Note: SARA may not detect disease progression for the frst fve to seven years. \u2022 Electrooculographic tests may be performed every two years (cooperation is required). \u2022 Brain MRI volumetry every two years \nEvaluation of Relatives at Risk \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.",
      "token_count": 462,
      "sentence_count": 30
    },
    {
      "id": "fam111a-dysp_txt_14",
      "contents": "$\\mathrm{{ADL=}}$ activities of daily living; $\\mathrm{CBC=}$ complete blood count; ${\\mathrm{KCS}}=\\mathbb{I}$ Kenny-Cafey syndrome; $\\mathrm{MOI}=$ mode of inheritance; $\\mathrm{OCS}=$ osteocraniostenosis; $\\mathrm{OT}=$ occupational therapy; $\\mathrm{PT}=$ physical therapy   \n1. Medical geneticist, certifed genetic counselor, certifed advanced genetic nurse \nTreatment of Manifestations \nSupportive care by a multidisciplinary team ofen includes pediatric endocrinologists, orthopedic surgeons, pulmonologists (for those with osteocraniostenosis) ophthalmologists, dental surgeons, hematologists, occupational therapists, physical therapists, and psychologists. \nSurveillance \nEvaluation of Relatives at Risk \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nWhen prenatal ultrasound was performed, the most prominent clinical features of osteocraniostenosis (OCS) detected were cloverleaf-shaped skull, intrauterine growth defciency, limb undergrowth, and occasionally intrauterine bone fractures. Most fetuses presented with these features at 20 weeks' gestation [Rosato et al 2022]. When OCS is suspected prenatally, referral should be made to a maternal-fetal medicine specialist for assessment and management advice. Management of an afected pregnancy is determined following discussion between the medical team and family regarding prognosis and the need for aggressive lifesaving measures in survivors. Tis is ofen center specifc. Indicators of lethality on ultrasound can provide additional information. Consensus guidelines on perinatal management of skeletal dysplasias have been published [Savarirayan et al 2019]. \nSee MotherToBaby for further information on medication use during pregnancy. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \n",
      "token_count": 469,
      "sentence_count": 21
    },
    {
      "id": "isovaleric-a_txt_1",
      "contents": "Supportive care: Routine daily treatment includes education of afected individuals and caregivers about the natural history, maintenance and emergency treatment, prognosis, and risks of acute encephalopathic crises; emergency treatment letter and MedicAlert ; management of movement disorder per neurologist; physical therapy and aggressive rehabilitation therapy for gross motor delay; notify metabolic center prior to planned surgeries; consult metabolic disease specialist with any emergency surgery/procedure. \n\nEmergency outpatient treatment includes carbohydrate supplementation orally or via tube feeding, transient reduction of natural protein intake, elevation of carnitine supplementation, and glycine; antipyretics for fever; antiemetics for vomiting. \nAcute inpatient treatment includes stopping protein intake, intravenous glucose, and hydration with normal saline; adjusting treatments for new or evolving neurologic manifestations; consider bufers as needed for lifethreatening metabolic acidosis; nitrogen scavengers for hyperammonemia. \nSurveillance: Quantitative analysis of plasma amino acids at least every three months until age one year, every six months from age one to six years, and annually in those age six years and older; blood gases, albumin, calcium, phosphate, parathyroid hormone, complete blood count, and vitamin $\\mathtt{B}_{12}$ at least annually in those on a proteinrestricted diet; measurement of growth and head circumference at each visit throughout childhood; monitor weight throughout adulthood; monitor developmental milestones at each visit; neuropsychological testing and standardized quality-of-life assessments as needed; assessment of movement disorder at each visit. \nAgents/circumstances to avoid: Excess of dietary protein or protein malnutrition inducing catabolic state;   \nprolonged fasting; catabolism during illness. \nEvaluation of relatives at risk: Biochemical or molecular genetic testing of all at-risk sibs of any age is warranted to allow for early diagnosis and treatment of classic IVA. \nGenetic counseling \nClassic IVA is inherited in an autosomal recessive manner.",
      "token_count": 422,
      "sentence_count": 9
    },
    {
      "id": "plpbp-def_txt_16",
      "contents": "\u2022 Full neurologic examination, including evaluation of eye movements and muscle tone (for hypotonia or rigidity) and description of seizure semiology \u2022 EEG, including sleep and wake cycles (preferably with a recording time of two hours) \u2022 Physical examination, including measurement of weight, length, and head circumference \u2022 Consultation with a medical geneticist, certifed genetic counselor, or certifed advanced genetic nurse to inform afected individuals and their families about the nature, mode of inheritance, and implications of PLPBP defciency in order to facilitate medical and personal decision making \nTo support the family of an individual diagnosed with PLPBP defciency, review of the following options is recommended: \n\u2022 Use of community or online resources (e.g., Parent to Parent)   \n\u2022 Social work involvement for parental support   \n\u2022 Home nursing referral (if needed)   \n\u2022 Ethics consultation (clinical ethics services) to assess health care decisions in the context of the best interest of the child and the values and preferences of the family \nTreatment of Manifestations \nTere is no cure for PLPBP defciency. \nTargeted Therapy \nIn GeneReviews, a targeted therapy is one that addresses the specifc underlying mechanism of disease causation (regardless of whether the therapy is signifcantly efcacious for one or more manifestation of the genetic condition); would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure. \u2014ED \nIndividuals with PLPBP defciency require pharmacologic treatment with vitamin $\\mathtt{B}_{6}$ for life [Hoytema van Konijnenburg et al 2021]. Te two forms of vitamin $\\mathtt{B}_{6}$ used in treating PLPBP defciency are pyridoxine (PN) and pyridoxal $5^{\\prime}$ -phosphate (PLP). \nPN is the frst-line therapy. Te majority of individuals have a favorable response to PN: $79\\%$ were seizure free and $10\\%$ had good seizure control [Heath et al 2020]. Of the remainder, $3\\%$ had only partial control and $8\\%$ had no improvement. \n",
      "token_count": 476,
      "sentence_count": 16
    },
    {
      "id": "fam111a-dysp_txt_1",
      "contents": "Surveillance: For individuals with KCS and OCS, assess anthropometry (height, weight, growth velocity, limb proportions, and upper-to-lower segment proportions) at each visit; clinical examination for scoliosis at each visit, with referral to orthopedics and physical therapy as necessary; assess functional limitations and assessment with physical therapy and/or occupational therapy as needed; measurement of serum calcium, phosphate, and vitamin D every three months until calcium level is normalized on treatment and then subsequently every six months; clinical examination for manifestations of hypocalcemia; abdominal ultrasound to assess for nephrocalcinosis and/or nephrolithiasis annually while on treatment; ophthalmology examination annually or as indicated; dental examinations every six months; assess for clinical manifestations of anemia at each visit; monitor developmental progress and educational needs at each visit throughout childhood; assess for changes in mood, afect, and/or psychosocial stressors at each visit; assess care coordination needs and genetic counseling needs at each visit. \nGenetic counseling \nFAM111A-related skeletal dysplasias (including KCS and OCS) are autosomal dominant disorders. \n\u2022 KCS. Most individuals diagnosed with KCS have the disorder as the result of a de novo FAM111A pathogenic variant. Rarely, individuals diagnosed with KCS have an afected parent. If a parent of the proband is known to have the pathogenic variant identifed in the proband, the risk to the sibs of inheriting the pathogenic variant is $50\\%$ . Each child of an individual with KCS has a $50\\%$ chance of inheriting the FAM111A pathogenic variant.   \n\u2022 OCS. With one possible exception, all probands reported to date with OCS whose parents have undergone molecular genetic testing have the disorder as the result of a de novo FAM111A pathogenic variant. Given that probands with OCS typically have the disorder as the result of a de novo FAM111A pathogenic variant, the risk to other family members is presumed to be low. \nOnce the FAM111A pathogenic variant has been identifed in an afected family member, prenatal and preimplantation genetic testing are possible. \nGeneReview Scope \n",
      "token_count": 492,
      "sentence_count": 11
    },
    {
      "id": "edm-ad_txt_9",
      "contents": "To establish the extent of disease and needs in an individual diagnosed with multiple epiphyseal dysplasia (MED), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended: \nElicitation of pain history   \nAssessment of joint mobility   \nRadiographs to determine the extent and severity of joint involvement   \nConsultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nFor pain control, a combination of analgesics and physiotherapy including hydrotherapy is helpful to many afected individuals; however, pain can be difcult to control. Referral to a rheumatologist or pain specialist may be indicated. \nLimitation of joint destruction and the development of osteoarthritis is a goal. Consultation with an orthopedic surgeon can determine if realignment osteotomy and/or acetabular osteotomy may be helpful in slowing the progression of symptoms. \nIn some individuals, total joint arthroplasty may be required if the degenerative hip changes are causing too much pain or dysfunction. \nPsychosocial support addressing issues of short stature, chronic pain, disability, and employment is appropriate. \nSurveillance \nEvaluation by an orthopedic surgeon is recommended if the afected individual has chronic pain or limb deformities (genu varum, genu valgum). \nAgents/Circumstances to Avoid \nTe following should be avoided: \nObesity, which increases stress on joints \u2022 Exercise that causes repetitive strain on afected joints \nEvaluation of Relatives at Risk \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \n",
      "token_count": 484,
      "sentence_count": 27
    },
    {
      "id": "sotos_txt_13",
      "contents": "To establish the extent of disease and needs in an individual diagnosed with Sotos syndrome, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended [TattonBrown & Rahman 2007]: \n\u2022 A thorough history to identify known features of Sotos syndrome: learning difculties, cardiac and renal anomalies, seizures, and scoliosis   \n\u2022 Physical examination including cardiac auscultation, blood pressure measurement, and back examination for scoliosis   \n\u2022 Investigations to detect abnormalities before they result in signifcant morbidity or mortality: \u26ac In children in whom the diagnosis has just been established, echocardiogram and renal ultrasound examination \u26ac In adults in whom the diagnosis has just been established, renal ultrasound examination to evaluate for kidney damage from quiescent chronic vesicoureteral refux \u26ac Referral for audiologic assessment. Conductive hearing loss may occur at an increased frequency in Sotos syndrome; thus, the threshold for referral should be low. \n\u2022 Consultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nWhen clinical manifestations (e.g., cardiac anomalies, renal anomalies, scoliosis, or seizures) are identified, referral to the appropriate specialist is recommended. \nIf brain MRI has been performed and ventricular dilatation demonstrated, shunting should not usually be necessary as the \"arrested hydrocephalus\" associated with Sotos syndrome is typically not obstructive and not associated with raised intracranial pressure. If raised intracranial pressure is suspected, investigation and management in consultation with neurologists and neurosurgeons would be appropriate. \nDevelopmental Delay / Intellectual Disability Management Issues \nFor difculties with learning/behavior/speech that can be found in individuals with Sotos syndrome, the following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. \nAges 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states. \nAges 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed. \n",
      "token_count": 493,
      "sentence_count": 19
    },
    {
      "id": "schmid-mcd_txt_1",
      "contents": "Schmid metaphyseal chondrodysplasia (SMCD) is characterized by progressive short stature that develops by age two years. Te clinical and radiographic features are usually not present at birth, but manifest in early childhood with short limbs, genu varum, and waddling gait. Facial features and head size are normal. Radiographs show metaphyseal irregularities of the long bones (e.g., splaying, faring, cupping); shortening of the tubular bones; widened growth plates; coxa vara; and anterior cupping, sclerosis, and splaying of the ribs. Mild hand involvement ofen includes shortening of the tubular bones and metaphyseal cupping of the metacarpals and proximal phalanges. Platyspondyly and vertebral end-plate irregularities are less common. Hand and vertebral involvement can resolve with age. Early motor milestones may be delayed due to orthopedi complications. Intelligence is normal. Joint pain in the knees and hips is common and may limit physical activity. Adult height is typically more than 3.5 SD below the mean, although a wide spectrum that overlaps normal height has been reported. Tere are no extraskeletal manifestations. \nDiagnosis/testing \nTe diagnosis of SMCD is established in a proband with characteristic clinical and radiographic features and/or identifcation of a heterozygous pathogenic variant in COL10A1 by molecular genetic testing. \nManagement \nTreatment of manifestations: Management of orthopedic complications by orthopedist, physiotherapist, occupational therapist, and pain specialist as indicated. Joint-friendly exercise, weight management; mobility device as needed; corrective osteotomy by guided growth surgery or valgus osteotomy may be considered in late childhood / adolescence in those with progressive or symptomatic varus deformity, signifcant coxa vara, triangular fragment in the interior femoral neck, or poor or deteriorating function; exercise and support from nutritionist to maintain healthy weight; psychosocial support; environmental or occupational modifcations as needed for short stature with recommendations from occupational therapy as needed. \nSurveillance: Annual growth assessment, clinical evaluation for orthopedic manifestations, and psychosocial evaluation. \n",
      "token_count": 484,
      "sentence_count": 19
    },
    {
      "id": "pitt-hopkins_txt_12",
      "contents": "\u2022 Child neurology evaluation to establish a neurologic baseline and evaluate for other neurologic issues such as sleep dysfunction or seizures. Tis should be expedited if there are familial concerns about seizure activity. Consider a baseline polysomnogram to assess for sleep disturbances.   \n\u2022 Ophthalmology evaluation to evaluate for myopia, astigmatism, and/or strabismus   \n\u2022 Gastroenterology evaluation to establish treatment regimen for chronic constipation and other possible GI issues such as gastroesophageal refux   \n\u2022 Musculoskeletal evaluation by an orthopedist or physiatrist to evaluate ambulatory skills and need for special mobility equipment and/or orthotics to aid in foot position   \n\u2022 Consultation with a clinical geneticist and/or genetic counselor \nTreatment of Manifestations \nDevelopmental Delay / Intellectual Disability Management Issues \nTe following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country. \nAges 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states. \nAges 3-5 years. In the US, developmental preschool through the local public school district is recommended.   \nBefore placement, an evaluation is made to determine needed services and therapies and an IEP is developed. \nAges 5-21 years \n\u2022 In the US, an IEP based on the individual's level of function should be developed by the local public school district. Afected children are permitted to remain in the public school district until age 21. \u2022 Discussion about transition plans including fnancial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood. \nAll ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. \nConsideration of private supportive therapies based on the afected individual's needs is recommended. Spe cifc recommendations regarding type of therapy can be made by a developmental pediatrician. \nIn the US: \n\u2022 Developmental Disabilities Administration (DDA) enrollment is recommended.",
      "token_count": 475,
      "sentence_count": 25
    },
    {
      "id": "26431_txt_216",
      "contents": ", fidgeting, shifting weight, and contracting the leg muscles). While helpful in day-to-day life, these constitute partial treatment during the diagnostic test. Box B-1 provides the instructions and reporting form for conducting the passive standing test used in the Johns Hopkins Chronic Fatigue Clinic. \nFew investigations have compared the available orthostatic testing methods. Among the studies that have compared tilt testing and active standing, none have examined prolonged upright posture (Hyatt et al., 1975; Plash et al., 2013). During the first 5 minutes upright, similar heart rate changes occur during active standing and tilt testing (Hyatt et al., 1975). Beyond the first 5 minutes, however, passive tilt provokes a larger \nCopyright National Academy of Sciences. All rights reserved. \nBOX B-1 Methods and Reporting Form for the Passive Standing Test \nPASSIVE STANDING TEST: \nThe following is a modifcation of the passive standing test (Hyatt et al., 1975) that has been used in the Chronic Fatigue Clinic at Johns Hopkins Hospital since the mid-1990s. \nThe standing test begins with the subject lying supine, with an automated blood pressure (BP) cuff set to record BP and heart rate (HR) at 1-minute intervals. The subject is supine for 5 minutes. The baseline HR and BP are measured and recorded each minute for 5 minutes supine. At the 4\u20135 minute point, record the intensity of the patient\u2019s current symptoms (on a 0\u201310 scale). \nThe patient is then instructed to stand, with the heels 2\u20136 inches away from the wall, and with the upper back leaning against the wall in a comfortable but motionless position for a maximum of 10 minutes. Each minute, HR and BP are recorded and the patient is asked about symptoms, for a maximum of 10 minutes upright. At the conclusion of the standing period, the patient is instructed to lie supine again, while the BP, HR, and symptom intensity are measured for a further 2 minutes. \nSpecifc instructions are as follows: \n\u201cWe\u2019d like you to stand as still as possible for up to 10 minutes. During the standing test you must be as motionless as possible in order to get an accurate result. Therefore, try not to wiggle your toes or fngers, scratch your nose, or move your arms or legs.",
      "token_count": 482,
      "sentence_count": 25
    },
    {
      "id": "rtps_txt_1",
      "contents": " Most individuals are treated using intensive multimodal therapeutic strategies \u2013 according to institutional preference \u2013 combining surgery, radiotherapy, and chemotherapy. Te intensive multimodal treatment strategies required for clinically aggressive tumors in children with RTPS lead to a high rate of secondary complications. Consider riskreducing treatment strategies (e.g., postpone or replace radiotherapy with high-dose chemotherapy or proton beam therapy; use targeted therapy concomitantly with, or before, standard chemotherapy). \nPrevention of primary manifestations: Prophylactic risk-reducing bilateral salpingo-oophorectomy may be discussed following the end of family planning in women with SMARCA4-related RTPS because of the high risk of developing SCCOHT. Te medical and ethical ramifcations involved require an interdisciplinary approach including counseling and further research. \nSurveillance: For all individuals with a disease-causing germline variant in SMARCB1 or SMARCA4 (regardless of age), whole-body MRI should be ofered at diagnosis: \n\u2022 Birth to age six months. Monthly (or at least every 2-3 months) thorough clinical examination including neurologic examination, ultrasound of the abdomen and neck, and head ultrasound or brain and spine MRI or whole-body MRI   \n\u2022 Age seven to 18 months. Every two to three months, thorough clinical examination including neurologic examination and ultrasound of the abdomen and neck. Consider brain and spine MRI as whole-body MRI resolution may not be sufcient for brain structures.   \n\u2022 Age 19 months to fve years. Every three months, thorough clinical examination including neurologic examination, ultrasound of the abdomen and neck, and brain and spine MRI.   \n\u2022 Afer age fve years. Every six months, thorough clinical examination including neurologic examination and annual whole-body MRI. Individuals with SMARCA4-related SCCOHT should have an abdominal and pelvic ultrasound every six months. \nEvaluation of relatives at risk: It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an afected individual to identify as early as possible those who would beneft from prompt initiation of tumor surveillance. \nGenetic counseling \nRTPS is inherited in an autosomal dominant fashion. Te vast majority of individuals with SMARCB1-related RTPS have a de novo disease-causing SMARCB1 germline variant.",
      "token_count": 486,
      "sentence_count": 21
    }
  ],
  "scan_analyses": [
    {
      "scan_type": "ECG",
      "scan_date": "2025-03-25T09:09:28.833517",
      "file_name": "norm.png",
      "description": "ECG Scan for Patient",
      "analysis": "Okay, let's analyze this ECG tracing. Here's a detailed breakdown of what I observe, considering it's an ECG scan for a patient:\n\n**Overall Impression:**\n\nThe ECG shows a sinus rhythm, but with some notable findings that warrant further investigation. The rate appears to be around 75 bpm, which is within the normal range. However, there are some concerning changes that suggest potential underlying cardiac issues.\n\n**Detailed Observations:**\n\n1. **Rate:** The heart rate is approximately 75 beats per minute (BPM). This is within the normal range (60-100 BPM). The rhythm appears regular.\n\n2. **R-R Interval:** The intervals between R waves (R-R intervals) are consistent, indicating a regular rhythm.\n\n3. **P Waves:** P waves are present and appear generally normal in morphology. They are upright in leads I, II, aVL, V1, V2, V5, and V6.  However, in lead aVR, the P wave is inverted, which can be seen with certain precordial orientations.\n\n4. **PR Interval:** The PR intervals are within the normal range (0.12-0.20 seconds). \n\n5. **QRS Complex:** This is where the most significant abnormalities are observed.\n   * **QRS Duration:** The QRS complexes appear slightly prolonged, with durations ranging from 0.08 to 0.12 seconds. This prolongation is a key finding.  Normal QRS duration is typically less than 0.10 seconds.\n   * **Morphology:** The QRS complexes are notched and appear somewhat bizarre in leads V1 and V6. This suggests some degree of ventricular depolarization abnormality.  There is a prominent R wave in V1 and V6, which could be indicative of some degree of left ventricular hypertrophy. \n\n6. **ST Segment and T Waves:**\n   * **ST Segment:** The ST segments are generally isoelectric (flat) except for a subtle depression in V4-V6. This could be associated with the QRS prolongation.\n   * **T Waves:** The T waves are predominantly negative, and show some inversion in V1-V3.\n\n7. **Axis:** The QRS axis appears to be predominantly right, as indicated by the upright QRS complexes in leads I, aVF, and V1.  However, the slightly prolonged QRS duration and the morphology"
    }
  ],
  "medical_entities": {
    "HISTORY": [
      "DOB",
      "2006-02-16",
      "Male",
      "history of illness"
    ],
    "SIGN_SYMPTOM": [
      "Complaint",
      "headache",
      "P waves",
      "P wave",
      "R wave",
      "depression",
      "QRS prolongation",
      "inversion",
      "S"
    ],
    "DIAGNOSTIC_PROCEDURE": [
      "physical exam",
      "assessment",
      "IMAGING",
      "S",
      "ECG",
      "ECG tracing",
      "rhythm",
      "rate",
      "heart rate",
      "R-R Interval",
      "between R waves",
      "-R intervals",
      "P Waves",
      "leads I",
      "II",
      "VL",
      "1",
      "6",
      "recordial",
      "PR Interval",
      "PR intervals",
      "QRS Complex",
      "QRS Duration",
      "QRS complexes",
      "S duration",
      "ology",
      "leads",
      "ST Segment",
      "T Waves",
      "ST segments",
      "T waves",
      "QRS axis",
      "QR",
      "complexes",
      "leads I, aVF",
      "V1",
      "QRS duration"
    ],
    "LAB_VALUE": [
      "P",
      "sinus",
      "75 bpm",
      "75 beats per minute",
      "BPM",
      "regular",
      "consistent",
      "normal",
      "upright",
      "inverted",
      "within",
      "0.12",
      "0.20 seconds",
      "slightly prolonged",
      "0.",
      "seconds",
      "0.10 seconds",
      "notched",
      "bizarre",
      "isoelectric",
      "flat",
      "negative",
      "right",
      "prolonged"
    ],
    "DETAILED_DESCRIPTION": [
      "25/2025",
      "-03-25T09:09:28.833517",
      ",",
      ", a",
      ", V",
      ", V2, V5, and V",
      "lead"
    ],
    "DURATION": [
      "2025"
    ],
    "DISEASE_DISORDER": [
      "cardiac issues",
      "ventricular depolarization abnormality",
      "left ventricular hypertrophy"
    ],
    "BIOLOGICAL_STRUCTURE": [
      "aVR",
      "V1 and V6",
      "V4-V6",
      "V1-V3"
    ],
    "DISTANCE": [
      "08",
      "0.12"
    ],
    "SEVERITY": [
      "prominent",
      "subtle"
    ]
  },
  "analysis_date": "2025-03-25T14:36:59.708891",
  "created_at": "2025-03-25T14:36:59.708895"
}